1. Home
  2. SNCY vs DBVT Comparison

SNCY vs DBVT Comparison

Compare SNCY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sun Country Airlines Holdings Inc.

SNCY

Sun Country Airlines Holdings Inc.

HOLD

Current Price

$15.29

Market Cap

766.5M

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$17.25

Market Cap

769.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNCY
DBVT
Founded
1982
2002
Country
United States
France
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
766.5M
769.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SNCY
DBVT
Price
$15.29
$17.25
Analyst Decision
Buy
Buy
Analyst Count
7
7
Target Price
$19.00
$31.75
AVG Volume (30 Days)
737.6K
601.3K
Earning Date
02-02-2026
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
28.51
N/A
EPS
1.05
N/A
Revenue
$1,106,213,000.00
$5,502,000.00
Revenue This Year
$6.16
$1,768.71
Revenue Next Year
$8.41
$1,028.88
P/E Ratio
$14.60
N/A
Revenue Growth
4.27
N/A
52 Week Low
$8.10
$3.33
52 Week High
$18.59
$26.19

Technical Indicators

Market Signals
Indicator
SNCY
DBVT
Relative Strength Index (RSI) 65.34 46.77
Support Level $14.19 $16.49
Resistance Level $15.86 $18.33
Average True Range (ATR) 0.49 1.20
MACD -0.01 -0.51
Stochastic Oscillator 66.73 8.00

Price Performance

Historical Comparison
SNCY
DBVT

About SNCY Sun Country Airlines Holdings Inc.

Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: